ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (SEHK: 1541)
Health Care · Biotechnology · CN
HK$3.13
-7.54% today · -74.2% 1Y
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (SEHK: 1541) operates in the Biotechnology industry within the Health Care sector. The company is valued at $171.05M and employs 202 people.
Over the last twelve months the share price has lost 74.2%, trading between 2.80 and 14.59.
Tweenvest scores ImmuneOnco Biopharmaceuticals (Shanghai) Inc. across four factors: quality 39/100, value 38/100. Its strongest factor is quality.
1541 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $171.05M
- Revenue (TTM)
- $21.72M
- P/E
- —
- EPS
- -0.54
- Dividend yield
- —
- Beta (5Y)
- 0.24
- 52-week high
- HK$14.59
- 52-week low
- HK$2.80
- Avg volume (3M)
- —
- Shares outstanding
- 429.54M
- Employees
- 202
- Next earnings
- —
About ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. is a biotechnology firm primarily dedicated to advancing immunotherapeutic treatments for various cancers. At the forefront of its development pipeline is IMM01, a CD47-targeting molecule currently undergoing clinical investigation. This lead candidate is being evaluated for its efficacy across a broad spectrum of malignancies, including myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), classical Hodgkin lymphoma (cHL), non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), head and neck squamous cell carcinomas (HNSCC), and colorectal cancer (CRC). Beyond its primary program, the company boasts a robust portfolio of experimental therapies. These comprise IMM0306, a bispecific CD47×CD20 molecule aimed at relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL); IMM2902, another bispecific agent combining CD47 and HER2 for solid tumors that are either HER2-positive or HER2-low expressing; and IMM2520, a bispecific CD47×PD-L1 molecule intended for various solid tumors. Further development efforts include IMM47, a humanized monoclonal antibody designed to target CD24 for cancer treatment; MM4701, a distinct bispecific molecule simultaneously engaging both CD47 and CD24; IMM2510, a bispecific "mAb-Trap" engineered to block both VEGF and PD-L1; IMM27M, a CTLA-4 antibody enhanced for ADCC activity; and IMM40H, a humanized IgG1 CD70 monoclonal antibody also featuring augmented ADCC activity. The company was established in 2015 and is headquartered in Shanghai, China.
- ISIN
- CNE100006624
- Founded
- 2015
- Listed since
- Sep 5, 2023
- Exchange
- The Stock Exchange of Hong Kong Ltd.
- Currency
- HKD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| GC Genome CorporationKOSDAQ: A340450 | $173.64M | ₩9,870.00 | +11.15% |
| TYK Medicines, IncSEHK: 2410 | $173.28M | HK$3.54 | -17.79% |
| PepGen Inc.NasdaqGS: PEPG | $172.46M | $2.49 | -4.96% |
| Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd.SEHK: 2566 | $172.36M | HK$5.64 | -2.51% |
| Dx & Vx Co., Ltd.KOSDAQ: A180400 | $170.59M | ₩2,330.00 | -1.48% |
| HEM Pharma Inc.KOSDAQ: A376270 | $169.45M | ₩31,600.00 | -9.06% |
| Medigen Biotechnology Corp.TPEX: 3176 | $168.61M | NT$— | — |
| Canton Strategic Holdings, Inc.NasdaqCM: CNTN | $168.13M | $2.11 | 0.00% |
Figures last refreshed Oct 11, 2026.